Liquidia Corporation reported second-quarter 2026 net product sales of approximately $170.4 million for YUTREPIA, up 31% from the first quarter and from $6.5 million a year earlier, helping drive net income of $74.7 million and adjusted EBITDA of $96.3 million. The company said YUTREPIA had received about 5,900 unique prescriptions and started more than 5,000 patients on treatment since its June 2025 launch. Alongside the commercial update, Pharmosa Biopharm, Liquidia's licensing partner for L606, said Liquidia has entered a heavier investment phase for the late-stage L606 program, with second-quarter Re-Spire spending of about NT$350 million, or US$10.8 million, and overall R&D in the second half of 2026 expected by Liquidia to be about twice first-half levels, with further increases anticipated in 2027.